LAG3 and neoplasm: LAG-3 has emerged as a pivotal mediator of immunosuppression in melanoma, interacting with MHC-II molecules within the tumor microenvironment (TME) to induce tolerogenic plasmacytoid dendritic cells (pDCs) independently of Toll-like receptors (TLRs), thus sustaining an immunosuppressive milieu (34).